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WHENEVERthe management ofbreast canceris underdiscussion, aswith cancer
in general, it is only natural to stress the importance ofearly diagnosis and prompt
treatment. Halsted (1895) considered that not even a single day should be lost
in instituting treatment for breast cancer, and since then the general teaching has
always been that the greater the delay the worse the prognosis. This view is often
linked with the opinion that if patients receive early treatment the outlook is
necessarily good. Efforts are, therefore, being made at the present time to
persuade patients with symptoms suggestive of cancer to overcome their fears and
to come forward promptly for medical advice. Some physicians, through cancer
detection centres and by teaching self-examination of the breasts, are striving to
find tumours before symptoms develop spontaneously.
A few years ago our complacency in demanding early treatment for cancer and
our faith in its effectiveness was shaken by McKinnon (1951a, 1951b, 1954, 1955)
in Canada, and by Park and Lees (1951) in England. The fact that survival rates
for patients with breast cancer do not necessarily fall with increasing duration of
symptoms has been taken as indicating that delay is of little significance in
prognosis, and offurther evidence that outcome is unaffected by treatment.
Conflicting reports are to be found in the literature regarding the influence of
delay on prognosis in breast cancer. Whilst a few papers show a general reduction
in survival rate with increasing duration of symptoms (Luff, 1932; Nohrman,
1949; Waxman and Fitts, 1959), and this is evident in a series ofover 10,000 cases
reported by the Registrar-General (1952) from England and Wales, most authors
find only a slight or inconstant relationship between these factors. It is not
uncommon to see a somewhat better prognosis for patients attending within a
month or two compared with later cases, but in the experience of Delario (1960)
and also Hultborn and T6rnberg (1960) women treated within two weeks and
within four weeks respectively appear to fare no better than those coming later.
Haagensen and Stout (1942) found a reduction in the " cure" ratewith increasing
delay for their cases seen between 1915 and 1934, but were unable to confirm this
-observation in a later series between 1935 and 1942 (Haagensen and Stout, 1951).
Many authors find a better prognosis for patients with a history extending over
one to three years or more, compared with women having a shorter delay (Eggers
et al., 1941; Macdonald, 1942; Haagensen and Stout, 1942; Burdick and
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Chanatry, 1954; Haagensen, 1956; Berkson, 1962). In a previous report con-
cerning 470 cases (Bloom, 1950b) the 5-year survival rate for patients attending
within 3 months was 51 per cent, between 3 to 6 months 47 per cent, and after 12
months or more 52 per cent.
It is indeed a remarkable finding that patients who neglect the cancer in their
breast for a year, or even longer, not infrequently appear to have a comparable or
even better survival rate than do those women who seek advice after only a brief
delay. This experience is not confined to breast cancer, and is also seen in reports
concerning cancer of the stomach (Swynnerton and Truelove, 1952) and rectum
(Harnett, 1953).
With so many conflicting results it was decided to investigate the effect ofdelay
on the disease itself as well as on prognosis in a series of cases of breast cancer in
which theinfluenceofintrinsic tumourmalignancy(histologicalgrading)hadalready
been studied (Bloom and Richardson, 1957), and in which a prolonged period of
follow-up was now available.
Material
The series for the present study consisted of 1411 cases seen between 1936 and
1949 at the Middlesex Hospital, London. These cases have been the subject of a
previous inquiry in which the value ofhistological grading was investigated (Bloom
and Richardson, 1957) and the importance of combining both stage and grade for
prognosis emphasised (Bloom, 1958). Two patients, previously untraced, have
been included in the present study. The stage was known in 1393 cases; 468
were in stage 1, 548 in stage 2, 290 in stage 3, and 87 in stage 4 (Manchester
system, Paterson, 1948). Eighty-four per cent of the patients were treated by
radical or modified radical mastectomy with or without ancillary radiotherapy.
The remainder were treated mainly by irradiation, surgery being limited to simple
mastectomy, local excision or biopsy. All survival rates concerning these cases
are crude figures, no correction being made for natural deaths.
Information regarding duration of symptoms was available in 1263 cases
followed for 5 years, 1225 for 10 years, 951 for 15 years and 399 for 20 years. Of
the total cases, 64 per cent attended hospital within 6 months and 82 per cent
within one year. Less than half the patients (45 per cent) came within 3 months
and only 16 per cent within one month; 18 per cent delayed for more than one
year and 8 per cent for more than 2 years.
The correlation between delay and survival is shown in Table I and Fig. 1.
The 5-, 10- and 15-year survival rates are somewhat higher for patients treated
within 3 months, but the gain does not exceed 10 per cent when compared with
women who wait 3 to 6 months. After this time, the survival rate tends to
increase slightly and, in patients delaying for more than 3 years, generally exceeds
that for casestreated within 3 to 6months. Sincethe case groupswith aprolonged
delay are small in number, especially in the series followed for 20 years, those
patients with a delay exceeding one year have been grouped together in the lower
part ofthe table to show a more consistent trend in prognosis. On the whole, the
appearance ofthe survival curves in Fig. 1 is striking, only because ofthe verylittle
change that occurs with increasing delay.
This is the type ofevidence that is sometimes put forward to decry the value of
cancer educational programmes, to proclaim the futility of cancer detection
clinics, and to support the view that treatment ofbreast cancer does not materially
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TABLE I.-Delay and Prognosis
Delay
< 3 months
> 3-6
> 6-12 ,
>12-18 ,,
>18-24 ,,
> 2-3 years
> 3 ,,
Total
< 3 months
> 3-6 ,
> 6-12 ,,
> 1 year
5 Year
Cases Survival
(%)
. 571 53
. 235 . 44
. 232 . 45
. 58 . 52
. 65 51
. 39 . 49
. 63 . 56
.1263 . 50
. 571
. 235
. 232
. 225
53
44
45
52
10 Year
Cases Survival
(%)
.556 36
.231 . 29
.223 31
55 . 29
61 31
38 . 37
61 38
1225 33
. 556
. 231
. 223
. 215
36
29
31
33
15 Year
Cases Survival
(%)
425 . 24
191 . 19
172 . 25
40 . 28
47 . 21
34 . 32
42 . 21
20 Year
Cases Survival
(%)
180 . 16
83 . 18
79 . 19
19 . 16
20 . 25
9 . 11
9 . 22
951 . 24 . 399 . 18
. 425
. 191
. 172
. 163
24
19
25
25
. 180
. 83
. 79
. 57
16
18
19
19
influence survival. Does the information provided by simply correlating duration
of symptoms and survival give the true picture concerning the effect of delay on
prognosis? The purpose of this paper is to show that it does not.
The duration ofsymptoms in many cancer patients probably represents only a
small fraction of the total pre-treatment duration of the primary tumour (Collins
et al., 1956; Schwartz, 1961). The obvious question to be answered then is
whether carcinoma ofthe breast advances appreciably during the delayperiod and,
if so, whether this degree ofadvancement is important in the ultimate outcome.
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First, let us consider, step by step, the influence of delay on prognosis in the
light of certain individual tumour factors, such as size of primary growth, lymph
node involvement, the degree of this involvement, clinical stage and operability.
Following this, attention will be drawn to the intrinsic malignancy of breast
cancer, and emphasis will be placed on the value ofhistological grading with which
it is hoped to try and explain some ofthe difficulties associated with breast cancer
studies in general and with determining the true significance of delay in this
disease.
Tumour Size
Size and delay
Generally speaking, the trend is for smaller breast cancers to be found in
patients who seek advice early, and for a progressively greater proportion oflarger
tumours to be associated with increasing delay (Macdonald, 1942; Kaae, 1948;
Haagensen, 1956; Lalanne, 1962). This has been our experience at the Royal
Marsden Hospital (Rigby-Jones, 1962), and in the cases reported here from the
Middlesex Hospital (Table II). Since tumour size was expressed as inches in the
TABLE II.-Delay and Tumour Size
Tumour size (inches)
Delay
(months) <1 in. >4<1 in. >1<2 in. >2 in. Total
(%) (%) (%) (%) (%)
<1 . 10 39 40 11 (161) 100
<3 . 7 37 41 15 (411) 100
>3<6 10 36 36 18 (171) 100
>6<12 . 7 24 49 20 (152) 100
>12 7 23 46 24 (149) 100
majority of the notes this scale has been retained. Information regarding both
tumour size and delay was available in 883 cases. Approximately half of the
patients presenting within one month had tumours less than one inch diameter
whilst in 11 per cent the size exceeded 2 inches; in patients delaying more than
12 months 30 per cent had the small tumours and 24 per cent the larger ones.
Size and survival
The 5- to 20-year results according to tumour size are presented in Fig. 2.
Survival rate is seen to fall rapidly with increasing tumour diameter. Patients
with tumours, for example, of half-an-inch or less have a 5- and 10-year survival
rate of 70 and 46 per cent respectively, compared with only 13 per cent and 5
per cent for those with growths exceeding 3 inches. These findings are in keeping
with those of other observers such as Eggers et al. (1941), Geschickter (1945),
Adair (1949), Burdick and Chanatry (1954), McWhirter (1957, 1960), Eker et al.
(1958) and Hultborn and Tornberg (1960). Lane and his colleagues (1961), who
have recently drawn attention to the prognostic significance of the gross contour
of the primary tumour, found that size influenced survival only in those tumours
with an irregular outline and was without effect on cases with well-delineated
lesions. Only one of 37 patients in the present series with a tumour greater than
3 inches in diameter was alive 15 years after treatment, whereas 37 per cent of 65
women with lesions ofhalf-an-inch or less survived for this time (Fig. 2).
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By considering size of the breast tumour and duration of symptoms it is
possible to obtain some idea oftumour growth rate. Richards (1948) studied this
aspect of breast cancer and obtained a good correlation with prognosis, the faster
the growth rate the lower the survival rate. Both tumour size and delay have
been correlatedwithprognosis inthepresent series (Fig. 3). The effect ofthefaster
growing tumours is seen in the survival rate for cases presenting within 3 months
which, as one might expect, shows the greatest reduction with increasing tumour
size. The more slowly growing lesions produce the least change in survival rate,
and this is seen in cases presenting after a delay of 12 months or more.
It is evident that the outlook for women who seek treatment early varies
considerably, depending upon the size of their tumour at the first examination
(Fig. 3). Thus, of patients attending within 3 months with tumours of half-an-
inch orless, 86 per cent are alive at 5years, comparedwithonly 21 per cent ofthose
with lesions greater than 2 inches. After a delay of 12 months, 73 per cent of
patients with small carcinomas are alive, compared with 37 per cent of those
harbouring large tumours.
These findings point to the importance ofconsidering " intrinsic tumour malig-
nancy " when trying to evaluate the influence of delay in breast cancer, a matter
to be considered in detail in later sections of this communication.
Lymph Node Involvement
Lymph node involvement and delay
Although the risk ofaxillary node involvement is greater with increasing dura-
tion of symptoms, this often amounts to no more than a trend (Haagensen and
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Stout, 1942, 1951; Hoopes and McGraw, 1942; Park and Lees, 1951; Burdick
and Chanatry, 1954). In the present series the histological state of the axillary
nodes and the duration of symptoms were known in 1047 cases. Although the
relationship is not consistent, the general direction is towards a slightly higher
TABLE III. Delay and Axillary Involvement
Delay
< 1 month
>1 2 ,,
>2< 3 ,,
>3< 4 ,,
>4< 6
>6< 12 ,,
>1< 2 years
>2< 3 ,
> 3 ,,
Total
Axilla
Cases involved*
196 . 59-
162 . 61 . 58%
133 . 52 J
69 61 64% 134 66f 4
181 . 63
94 . 67 .67%
31 . 61
47 68 .68%
. 1047 61
* Histological assessment.
incidence of axillary metastases with increasing delay (Table III), The actual
extent or degree ofaxillary node involvement can also be related to delay as shown
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by the incidence ofapical (" level 3 ") axillary metastases in the report by Robbins
and Bross (1957) from the Memorial Hospital (Table IV).
TABLE IV.-Degree ofAxilla Involvement According to Delay
Delay Cases " Level 3 "
(months) axilla involvement
<2 . 550 . 28%
2-6 . 336 . 30%
>6 . 395 . 40%
Robbins and Bross (1957)
Involvement of the internal mammary chain has been correlated with the
extent of axillary node metastases by Handley and Thackray (1954) at the
Middlesex Hospital (Table V), and also by Tubiana (1964) at the Gustave Roussy
Institute (Table VI). Finally, it is in the presence ofaxillary metastases that the
stage is set for spread to the supraclavicular nodes.
TABLE V.-Internal Mammary Node Metasta3es According to Degree of Axilla
Involvement
Degree of With internal
axilla involvement Cases mammary metastases
(%)
Nil . . . 57 . 14
Slight . . . 23 . 26
Moderate . . 32 . 37
Heavy . . . 34 . 65
Handley and Thackray (1954)
TABLE VI.-Internal Mammary Node Involvement
Axillary nodes+ve . .0.1. 2 . 3 .4-5 .6-7. 8
Number ofcases . . . 35 . 29 . 23 . 17 . 18 . 19 . 23
Internal mammary nodes . (%) (%) (%) (%) (%) (%) (%)
-ve . 91 . 76 . 65 . 71 . 50 . 58 . 52
+ve . 9 .24 .35 .29 .50 .42 .48
Tubiana (1964)
Lymph node involvement and primary tumour size
A correlation exists between primary tumour size and axillary node metastases,
the larger the primary lesion the greater the likelihood of such metastases being
present (Eggers et al., 1941 ; Ackerman, 1952; Berg, 1955; Rennaes, 1960;
Lane et at., 1961). This relationship is more striking than that between delay and
tumour size, and also between delay and axillary involvement. In the present
series information regarding both tumour size and histological assessment of the
axillary nodes was available in 853 cases. Practically 50 per cent of the patients
with tumours half-an-inch or less in diameter had axillary metastases, compared
with 94 per cent ofthose with tumours exceeding 3 inches (Table VII).
Giacomelli and Veronesi (1952) and also Haagensen (Budinger, 1964) have
found that, with increasing size ofbreast tumour, metastases are more frequent in
the internal mammary lymph nodes.
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TABLE VII.-Primary Tumour Size and Axillary Involvement
Size Cases Axillary
(inches) involvement*
(%)
<1 . 70 . 49
>iA<1 . 280 . 49
>1<2 . 363 . 61
>2<3 . 104 . 76
>3 . 36 . 94
Total . 853 . 59
* Histological assessment.
Thus, with increasing primary tumour size, which is related to delay, or with
increasing delay per se, there is not only a higher incidence of axillary node meta-
stases, but the degree of this involvement is also greater. With increasing delay
and progressive axillary involvement, internal mammary and supraclavicular node
metastases become more frequent.
Lymph node involvement and survival
There is general agreement that in breast cancer the outlook for women with
axillary metastases is considerably worse than for patients without this complica-
tion. In the present series information regarding the condition of the axillary
nodes was available in 1311 cases, in 89 per cent ofwhich the assessment was from
histological sections (Table VIII). The 5-year survival rate for women without
axillary metastases was twice as great as for cases with such metastases; the
corresponding prognosis at 10, 15 and 20 years, when the axilla wasfree, was better
by a factor ofthree. four and nearly five. respectively.
TABLE VIII.-Axilla Involvement and Prognosis
Results
5 years 10 years 15 years 20 years
r * _
Axilla Cases Survival Cases Survival Cases Survival Cases Survival
(/) (/) (/) (/)
0 .520 73 . 497 55 . 384 43 . 172 31
+ .791 36 . 763 19 . 595 11 . 217 7
Total . 1311 50 . 1260 33 . 979 24 . 389 18
Less attention has been given to the fact that the actual number of axillary
glands involved, and the extent of this involvement, markedly affects prognosis
(Adair, 1949; Haagensen, 1956; Hultborn and Tornberg, 1960; Robbins, 1962),
(Tables IX and X). To determine the condition of the axilla accurately requires
an adequate dissection of this region during radical mastectomy, a careful search
for lymph nodes in the post-operative specimen, and subsequent examination of
multiple histological sections of these nodes. In many hospitals only a limited
examination of the axillary contents is carried out but, even so, a useful guide to
prognosis may be obtained from such material. A study was made ofthe routine
histological lymph node sections in the first 400 cases of the Middlesex series,
which included patients treated at Sector and other hospitals during the War
years. Although only a very rough assessment of the degree of axillary involve-
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TABLE IX.-Degree ofAxilla Involvement and Prognosis
Axillary 5-year 5-year local
nodes +yve Cases survival recurrence
(%o) (%)
1-2 67 75 8
3-7 62 . 53 21
8+ 61 26 48
Total 190 52 . 25
Haagensen (1956)
TABLE X.-Degree ofAxilla Involvement and Prognosis
Survival rate
Axilla ,
involvement Cases a years 10 years 15 years
(oo) (°h) (0)
0 .574 80 58 44
Level 1 +ve 164 . 61 41 30
Level 2 +ve 159 45 30 23
Level3 +ve 363 28 15 10
Robbins (1962)
-ment was possible in most cases from the limited histological sections available, a
correlation with survival was obtained (Table XI).
TABLE XI.-Axilla Involvement and Prognosis
Axilla involvement 5-year
(histological) Cases survivors
(0)
0 . . 175 125 66
++ . 86 38 44
T+ + . . 138 35 25
Total 399 198 50
0 = Nodes free
+ + = Moderate involvement of 1-2 nodes
+ + + = More extensive involvement
Metastases in the internal mammary lymph nodes alone is uncommon, and
appears to effect prognosis in much the same way as does axillary involvement.
On the other hand, when deposits are present in both these regions the outlook
seems to be exceedingly poor; only 1 of 29 such cases in Handley's (1962) series
survived 10 years.
The discovery of occult supraclavicular metastases in 10 to 20 per cent of
patients with axillary metastases, otherwise suitable for radical surgery (Dahl-
Iverson, 1956; Margottini, 1948; Haagensen, 1956), is a grave sign: only 3 of 17
such cases reported by Andreassen et al. (1954) survived 5 years.
At the beginning ofthis paper it was not possible to show that delay influenced
,survival appreciably. We now find that the factor of delay can be related to the
presence and to the extent of regional lymph node involvement, and that these
in turn are closely related to prognosis.
236DELAY AND BREAST CANCER
Extent ofthe Disease
Stage and delay
Clinical staging is a convenient way of combining several local factors con-
cerning the primary tumour together with the state of the axillary lymph nodes.
It is among those patients with a prolonged delay that a greater proportion of
tumours in the more advanced stages is to be found. A good correlation between
stage and delay is seen in the cases studied by Nohrman (1949), Shimkin et al.
(1952) (Table XII) and Lalanne (1962).
TABLE XII.-Delay According to Stage
Stage Median period of
(Portmann) Cases delay (months)
1 333 4-0
2 296 5*5
3 310 11*5
4 99 25 0
Shimkin et al. (1952)
In the present material information regarding both stage (Manchester system)
and delay was available in 1255 cases. A correlation between stage and delay is
seen when we consider the time in which a given proportion of patients attend for
treatment (Table XIII). For example, the upper quartile (when 75 per cent of
patients attend) for stage 1 cases is 7 3 months; stage 2 cases, 7 5 months; stage 3
cases, 13 months and stage 4 cases, 19 months.
TABLE XIII.-Delay According to Stage
Delay (months)
Stage 1 Stage 2 Stage 3 Stage 4
Group 419 cases 495 cases 267 cases 74 case3
Lower quartile . 1 2 1 2 2*4 2*5
Median . . 2 9 3-0 6 1 5- 8
Upper quartile . . 7 3 7-5 13-0 19.0
Lower quartile: time (months) within which 25% of cases attended
Median : ,, ,, ,, ,, 50% ", . .
Upper quartile : ,, ,, ,, 75% ,. . ..
With increasing duration ofsymptoms there is some variation in the incidence
of the different stages (Fig. 4), but up to 3 years the proportion of patients with
tumours in stage 1 or stage 2 clearly diminishes, whilst cases with lesions in the
more advanced stages increase. Thus of the 569 cases attending within three
months 38 per cent are confined to stage 1, whilst 18 per cent have extended to
stages 3 or 4 (Table XIV). The corresponding figures for 100 cases with a delay
TABLE XIV.-Incidence ofCases by Stage According to Delay
Delay Cases Stage 1* Stage 2* Stage 3+4*
(%) (%) (%)
< 3 months. . . 569 . 38 . 44 . 18
6-12 ,, . . 228. 32 . 34 . 34
> 2 years . . . 100 21 . 30 . 49
* Manchester staging
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exceeding 2 years is 21 per cent and 49 per cent respectively. For an intermediate
period ofdelay of between 6 and 12 months the proportion ofearly and advanced
cases is practically equal. A similar correlation between stage and duration of
symptoms has also been shown in cases at the Royal Marsden Hospital (Smithers,
1958).
Among the 62 patients in the present series with a delayexceeding 3 years there
is a sharp increase in the proportion of stage 2 tumours (Fig. 4). This is due,
presumably, to a preponderance of carcinomas ofrelatively slow growth rate and
of low biological potential since these cases, in spite ofneglect, have already been
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FIG. 4.-Stage incidence according to delay.
able to survive a considerable length oftime without treatment. Support for this
explanation is to be found in a later section of this paper when tumour grade is
considered in relation to delay (Table 17).
These results agree in the main with those reported by the Registrar-General
(1952) in an unselected series of over 21,000 cases of breast cancer registered in
England and Wales between 1945 and 1949. The median delay for patients with
tumours confined to the breast was 4-1 months, locally advanced lesions 9 1
months, and for those with distant metastases 114 months. The well-defined
correlation between stage of disease and duration of symptoms in the Registrar-
General's (1952) report has been confirmed in a second large series of cases from
the same source, registered between 1950 and 1954 (Spicer and Lipworth, 1965,
personal communication). Lalanne (1962) also found a greater incidence of
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distant metastases with increasing duration ofsymptoms: for a delay ofless than
2 months, 6 per cent of his patients had metastases compared with 12 per cent of
those waiting 6 to 12 months, and 26 per cent for a delayexceeding one year. In
this respect the experimental work of Zeidman and his colleagues (1950) is of
interest. These workers have shown in animals that thelonger a tumouris present
the greater the number ofemboli released, as judged by the number ofmetastases
appearing in the lungs.
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FIG. 5.-Stage and survival.
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It is evident that mammary cancer tends to progress to a more advanced stage
duringtheinterval between awoman first becoming aware ofa breast lump and the
time she finally comes under medical care.
Stage and survival
There is general agreement that survival in breast cancer falls profoundly with
increasing clinical stage ofthe disease. In the present series information regarding
stage was available in 1393 cases. The deterioration in prognosis according to
stage is seen in the 5-, 10-, 15- and 20-year results (Fig. 5).
Inoperability and Delay
Closelylinkedwithclinicalstageisthe question ofoperability. Withincreasing
delay fewer patients are suitable for radical mastectomy. Kaae (1948) found that
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of 84 cases seen within 2 weeks of onset of symptoms all were operable, compared
with 77 per cent of 140 patients presenting within 3 to 12 months. More recently,
Rennaes (1960) reported that of 421 cases presenting within one month at the
Norwegian Radium Institute, 91 per cent were operable compared with only 52 per
cent of 275 cases who waited for more than 12 months. The effect of delay on
radicaltreatment in alargeseries ofunselected casesis to be foundinthe Registrar-
General's (1952) report covering over 21,000 patients in England and Wales (Table
XV).
TABLE XV.-Cases Receiving Radical Treatment According to Delay
Delay (months) <2 <6 <12 >12
(0/) (0/) (0/) (0/)
Receiving radical treatment . 88 77 65 61
Registrar-General (1952)
21,508 cases
(1945-1949)
As far as we have gone the conclusion must be that with increasing delay the
primary tumourtends toincreasein size, theaxillary andinternalmammarylymph
nodes to become involved, the stage ofthe disease to advance, distant metastases
to be a greater risk, and operability to diminish. It would, therefore, seem
logical to expect the outlook for patients with breast cancer who come late for
treatment to be distinctlyunfavourablewhendelayitselfiscorrelatedwithsurvival.
We have seen that this is not the case, the survival often remaining remarkably
uniform in spite of increasing delay (Fig. 1). What factors may account for this
discrepancy?
So far, no attention has been given to the inherent properties of the tumour
itself, nor to possible local and systemic resistance factors on the part of the host.
It is true that suchfactors as size oftumour, growthrate, axillary involvement and
stage ofdisease reflect tumour potential, but only to a limited extent. Elsewhere,
(Bloom, 1950a, 1958) it has been shown that cases in any given stage ofthe disease
are composed of patients with tumours ofwidely differing degrees of malignancy,
the latter feature being conveniently expressed in terms of three histological
grades.
The concept of biological potential is complex in that although more malig-
nant tumours tend to increase in size, infiltrate quickly and disseminate early,
thesethree featuresneed notbein step (Foulds, 1951). Thus,asmallbreasttumour
may already have given rise to metastases by the time it is found by the patient.
On the other hand, a large tumour may still be confined to the breast, whilst other
growths become locally advanced with involvement of the axillary lymph nodes
but without distant metastases.
Histological Grading
Many reports indicate that the potential malignancy of breast cancer is
generally reflected in its histological architecture (Greenough, 1925; Patey and
Scarff, 1928; Geschickter, 1945; Harrington, 1946, 1952; Bloom, 1950a, 1950b;
Black et al., 1956; Haagensen, 1956; Bloom and Richardson, 1957).
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There has been much argument as to the prognostic significance of various
histological criteria, both parenchymal and stromal. The most consistent results
have been obtained by considering the degree oftubular differentiation, regularity
of nuclear size, shape and staining, and the frequency of hyperchromatic and
mitotic figures. Taking the histological picture as a whole, each tumour can be
classified as being of low (grade I), intermediate (grade II) or high (grade III)
malignancy. These three groups merely represent arbitrary subdivisions ofwhat
is, in fact, a continuous scale ofmalignancy. This subject and its problems have
been reviewed in detail elsewhere (Bloom, 1950a; Bloom and Richardson, 1957).
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Survival in the present series of cases according to grade of malignancy at 5-,
10-, 15- and 20-years from the time of treatment is shown in Table XVI and Fig.
6. A clear difference is seen for the three grades, the survival rate for patients
with grade I tumours being between two and three times greater than that for
grade III cases. Most ofthe deaths from grade III tumours take place in the first
5 years, whereas the mortality ofgrade I cases occurs at a considerably slower and
more uniform rate over the entire 20 years (Fig. 6).
The importance of grading breast cancer is further emphasised by a recent
study of untreated cases from the past records of the Middlesex Hospital Cancer
Charity between 1805 and 1933 (Bloom et al., 1962). In this series there were 86
cases, seen between 1902 and 1933, in which histological material was available.
Although the numbers in each group are small a striking difference is seen in the
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TABLE XVI.-Grade and Prognosis
5-year results 10-year results 15-year results 20-year results
(1936-49) (1936-49) (1936-47) (1936-42)
lr t~~~~ e-' r- A - Grade Cases Survivals Cases Survivals Cases Survivals Cases Survivals
(/) (0) (0) (0)
I 363 272 75. 347 180 52 .271 97 36 .135 34 25
II . 640 301 47 .613 178 29 .473 96 20. 192 27 14
III 408 131 32. 399 79 20 .326 45 14. 135 13 10
Total 1411 704 50 . 1359 437 32 1070 238 22 . 462 74 16
natural history of tumours of grade I and grade III malignancy (Fig. 7). At 5
years 22 per cent of grade I cases were alive, whereas all those with grade III
tumours were dead. After 10 years, 9per cent ofgrade I and 3 per cent ofgrade II
cases were still alive. The mean survival ofgrade I cases was 47-3 months (range
6 to 166); grade II, 39-2 months (range 5 to 122); grade III, 22 months (range 2
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FiG. 7.-Untreated breast cancer; histological grade and survival, Middlesex Hospital, 1902-1933
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to 53). The mean duration of symptoms and of life after admission to hospital
was more than twice as long for grade I as it was for grade III cases (Fig. 8)
(Bloom, 1964).
The influence ofaxillary node involvement on overall survival has already been
considered (Table VIII). The state ofthese nodes is now correlated with histolo-
gical grade for prognosis (Fig. 9). For clarity the survival ofcases with tumours of
low (grade I) and of high (grade III) malignancy only are shown in this figure.
Grade II cases occupied a well-defined intermediate position in the group with
axillary node metastases, but showed a comparable survival curve to grade III
cases when the axilla was free. The striking difference in outlook for patients with
axillary metastases, depending on whether they have grade I or grade III tumours,
is a clear example of the limited information which may be given in breast cancer
when only one factor of the disease is studied and when inherent malignancy is
neglected. Thus, the 10-year survival rate for all patients with axillary node
involvement is 19 per cent (Table VIII), but within this group 42 per cent ofgrade
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FIG. 9. Survival according to grade and axilla involvement.H. J. G. BLOOM
I cases are alive compared with a mere 9 per cent of those with grade III lesions
(Fig. 9). At 20 years, however, the difference in survival rate for these two grades
in the presence of axillary metastases is much smaller. When the axilla is free,
the difference between grade I and grade III cases is less marked, but better
maintained at 20 years.
Attention has been given to tumour size and prognosis (Fig. 2). Now the
influence of size on survival can be considered in the light of tumour grade (Fig.
10). Information regarding both size and grade was available in 989 cases fol-
lowed for 5 years. It is clear that outcome is generally dependent upon size, and
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FIG. 10.-Tumour size, grade and survival.
that this is greatly influenced by histological grade. Thus the prognosis for grade
I cases remains good whether the tumour is small or of moderate size: it is only
with the largest tumours in this grade that the outlook deteriorates appreciably.
The survival rate for grade III cases is considerably lower than that for grade I
cases and the influence of size is rather more marked. The outlook for patients
with tumours of intermediate malignancy (grade II) occupies an intermediate
position and shows the greatest change in survival with increasing tumour size.
The histological grade reflects the potential malignancy of breast cancer, and
indicates which cases are more likely to have occult blood-borne metastases at the
time oftreatment. Metastases, however, appear to be common to all three grades
oftumour when patients are first seen, and in such cases grading provides a guide
to the speedwithwhichthedeposits arelikelyto become active, produce symptoms
and cause death (Bloom and Richardson, 1957).
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Grade incidence and delay
With increasing duration of symptoms the number of patients with grade III
tumours diminishes, whilst the proportion ofessentially more benign grade I cases
increases. The incidence of these grades is approximately equal when the delay
is 6 to 12 months (Table XVII and Fig. II). Ofthe patients presenting within a
TABLE XVII.-Grade Incidence According to Delay (1263 Cases)
Delay Grade I Grade II Grade III Total
(/) (0) (0) (0)
< 3 months . . 23 . 45 . 32 .571 100
>3<6 ,, . 19 . 49 . 32 .235 100
>6.12 ,, . . 29 . 41 . 30 . 232 100
1-2 years . 35 . 41 . 24 123 100
2-3 ,, . 33 . 46 . 21 . 39 100
>3,, . 41 . 51 . .63 100
49 % GRADE n 51 % (567 CASES>
45 41
__ 46 %
GRADE I 41 % (325 CASES)
40
laR
3~~~~~~~~~~~3
32
3
%
32%S2
23 % / '~24 %
24 . % GRADE m (371 CASES>
10 8 %
DELAY I E I I
(MONTHS) (3 >3-6 >6-12 >12-24 >24-36 >36-48
CASES 571 235 232 123 39 63
FIG. 11.-Grade incidence according to delay (1263 cases)
months 23 per cent had grade I tumours and 32 per cent were grade III, compared
with 41 per cent and 8 per cent respectively forpatients waiting more than 3 years.
The proportion ofintermediate grade cases at the different periods ofdelay showed
little change.
Histological grade appears to be a neglected factor which may alter the
expected prognosis in breast cancer. Thus the promising outlook for a patient
who seeks treatment promptly with a small primary tumour, or a stage 1 or stage 2
lesion, may be modified unfavourably ifthe grade is high. Conversely, life may be
prolonged to a surprising extent in patients who present after a delay of 2 or even
3 years with locally advanced tumours of low histological grade.H. J. G. BLOOM
Delay and survival according to grade
In view of the above observations the influence of delay on survival was re-
examined in the light of tumour grade (Fig. 12). Initially, the survival rate is
seen to decrease for patients with grade I and also grade II tumours. After a
delay of between 12 and 24 months the survival rate for grade I cases recovers to
become comparable to that for cases attending within 3 months. In gradeII cases
there is little change in survival rate after 6 months. The poorest prognosis is
seen for patients with grade III tumours, and there appears to be no gain for those
who seek treatment early withthishighly malignant type oflesion. Although the
differences are not marked, this is the first positive direct correlation between delay
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FIG. 12.-Delay and prognosis according to grade (1263 cases); 5 year survival.
and survival found in the present series, at least for grade I and perhaps grade II
cases. A comparable survival pattern according to tumour grade and delay was
seen in 615 cases at the Royal Marsden Hospital (Smithers, 1958).
Combined Factorsfor Assessing Influence ofDelay
A more accurate assessment ofthe effect ofdelay on prognosis in breast cancer
may be achieved by combining some of the individual factors that have been
discussed. The subject now becomes more complex since many permutations are
possible using the size, stage and grade ofthe primary tumour, and the state ofthe
axillary lymph nodes for correlation with delay.
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Delay and survival according to tumour size and grade
First, let us consider size and grade of primary tumour, in relation to patient
delay and survival. Adequate information for this study was available in 883
cases (Fig. 13). It is clear that the patients coming within 3 months constitute a,
heterogenous group of cases with small and large tumours of different grades of
malignancy and with a 5-year survival rate ranging from 87 down to 30 per cent.
A similar state ofaffairs exists for the other periods ofdelay shown in Fig. 13.
In spite of some discrepancies, the prognosis for specific groups according to
grade tends to deteriorate with increasing duration of symptoms (Fig. 13). Thus
GRADE I1N I11M. I n1 X I m I a sum I11as
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FiG. 13. Prognosis according to delay, grade and size.
when the cases seekingtreatment within 3 months are comparedwith those coming
between 3 and 12 months, the survival rate is seen to fall for patients with tumours
ofless than one inch in diameter, whether the lesions, during such an interval, tend
to remain small or increase in size. A similar change in prognosis occurs for the
larger tumours, except that grade III cases appear to have a comparable survival
whether they are seen within 3 months or between 3 and 12 months. Since
spontaneous regression is exceptionally rare in breast cancer the cases with large
tumours are not to be compared with those coming after a longer interval with
small tumours (Fig. 13). The influence of duration of symptoms on survival
according to tumour grade and size is not upheld on passing from the intermediate
period ofdelay (3-12 months) to one exceeding 12 months. It is noteworthy that
the outlook for women with large tumours ofgrade I malignancy who delay for 3
2-17H. J. G. BLOOM
to 12 months orlonger, is better thanthatforpatients who present within 3 months
with small grade III lesions.
Delay according to stage and grade
The staging of breast cancer provides a valuable method of expressing the
extent of the disease and brings together various local tumour factors and the
condition oftheregionallymphnodeswhich, sofar,haveonlybeenusedindividually
to investigate the influence of delay in this disease. A simple combination of
stage and grade may, therefore, give the most comprehensive account of the
disease possible at the present time, being a measure of the potential malignancy
of the tumour and its obvious extent when first seen.
Stage ofdisease has already been related to delay (Table XIII; Fig. 4; Table
XIV). A more accurate correlation between tumour advancement and delay can
be achieved when cases are considered according to both grade and stage. For
each grade of tumour the time within which 25, 50 and 75 per cent of the cases
attended for treatment is seen in Table XVIII. With passing time each grade
advances in stage, and the higher the grade the faster the tumour's progress.
For example, in grade I malignancy 75 per cent ofstage I cases seek advice within
10 1 months, compared with 18 months for the same proportion of stage 3 cases.
The corresponding figures for grade II cases is 6-8 and 15 months, and for grade III
cases, 5-5 and 12 months.
TABLE XVIII.-Delay According to Stage and Grade
Stage
Grade 1 2 3 4
I . (147) 1.3* (111) 1-7 (56) 2-5 (9)Indeterminate 3*3t 4*6 8.3
10-1$ 11.9 18-0
II . . (188) 1 1 (222) 1 1 (119) 2*9 (35) 1.9 3*0 3*0 6*4 3*8
6-8 7-3 15-0 15.0
III . . (84) 1 3 (162) 1 3 (92) 1 4 (30) 3 1
2-5 2-5 4-6 6-5
5.5 5-6 12*0 13-0
() = Number ofcases
* Lower quartile: Time (months) within which 25% ofCases attended
t Median : , , ,, ,, 50/
$ Upper quartile: ,, ,, ,, ,, 75% ,,
Distribution of early and late stage cases according to grade and delay
It has already been shown that with increasing delay the proportion of cases
with tumours of limited stage falls whilst the incidence of the more advanced
stages increases (Fig. 4; Table XIV). This relationship can now be re-examined
in the light of tumour grade (Fig. 14). With increasing delay in grade I cases,
the trend is for stage 1 tumours to become fewer in number whilst those in stage 3
become greater. After a delay of more than 2 years the proportion in stage 3
exceeds that in stage 1. The corresponding " cross-over " in stage distribution
for grade II tumours is seen to take place just after 12 months, and for grade III
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tumours between 6 and 9 months. Once again cancer of the breast is shown to
advance with increasing duration ofsymptoms, and the higher the grade oftumour
the quicker the progress of the disease.
Delay and survival according to grade and stage
By combining clinical stage and histological grade a more accurate guide to
prognosis in breast cancer can be obtained than by either system alone (Bloom,
1950a, 1958). Within the framework ofthis combined classification the influence
of delay is to be found, and the results of its application support the view that
survival is adversely affected by increasing the delay (Fig. 15). With advancing
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FIG. 15.-Survival ofgrade I and grade III cases according to stage. Incidence of cases with short
and prolonged delay.
stage the survival rate is seen to fall steeply for grade III cases and more gradually
for grade I cases. The proportion ofpatients attending within 3 months and after
12 months is also shown for each group by the shaded columns. In both the grade
I and the grade III cases it is evident that with advancing stage and a falling sur-
vival rate the patients with a short delay decrease in number whilst those with a
prolonged delay increase. A similar picture was seen for grade II cases, the
survival ofwhich occupied anintermediate position to that ofthe other two grades.
Stage and gradefor prognosis
In using the combined classification of stage and grade for breast cancer it is
perhaps more convenient to group cases, as in previous communications (Bloom,
1950a, 1958), with sub-divisions according to grade (Fig. 16). It is clear that each
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stage is composed ofpatients with tumours ofwidely differing malignant potential,
emphasising the inadequacy of considering cases by stage alone, especially when
comparing treatment results. The survival rate within stage 2, for example,
varies from as high as 71 per cent for women with grade I tumours to as low as 26
per cent for those with grade III lesions. An important feature of this classifica-
tion is the revelation that patients with grade I breast cancer in the later stages of
the disease have a considerably better prognosis than do less advanced cases with
grade II or grade III tumours. Thus, the survival rate for stage 3 grade I cases is
comparable to that for stage 1 grade II, or stage 1 grade III cases. Note that
even stage 4 cases with grade I lesions have as good an outlook as the grade III
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FIG. 16.-Survival by stage and grade; 5-year results in 1393 cases.
cases in stage 2. A pattern ofsurvival similar to that at 5 years is seen in the 10-
and 15-year results, and to a lesser extent at 20 years (Fig. 17, 18, 19).
The application of this combined classification to patients with breast cancer
presenting for treatment within, say, 3 months and also after 12 months from the
onset of symptoms (Fig. 20 and 21), clearly emphasises the tremendous variation
in the type of case seeking early or even late advice. It highlights the futility of
trying to study the influence ofdelay, as well as other problems, in this disease by
single factors alone and without reference to inherent tumour malignancy.
DISCUSSION
It is not possible to determine the influence of delay on prognosis in breast
cancer without taking into account the intrinsic biological nature of the tumour.
Theslowgrowingtumours oflowgrademalignancy mustbe separatedfromthose of
rapid growth and high malignancy. The reason that some patients who delay
seekingtreatmentforlongperiods have asurprisinglyhighsurvivalrateis thatthey
represent a selected group of cases with a favourable prognosis based on the slow
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FIG. 17.-Survival by stage and grade; 10-year results in 1341 cases.
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progress oftheir tumours, or a high degree ofhost resistance, or both. As Berkson
(1962) has pointed out, they are the survivors of a larger group of cases in which
those with the more malignant tumours and poorest resistance have already been
eliminated by death.
One should also add that the influence of delay is often studied in patients
treated by radical surgery which automatically excludes many cases which have
become advanced and inoperable because of prolonged delay. McWhirter (1957)
found that patients with operable and locally advanced carcinoma of the breast
who delay for one year or more had a slightly higher survival rate than those
10
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FiG. 21.-Survival of patients with > 12 months' delay according to stage and grade.
who seek treatment within 3 months. When the cases with distant metastases
were included in the analysis a better prognosis was seen for patients who presented
early, the incidence ofdistant metastases being much greater in those who delayed
for a year or more. In a later report (McWhirter, 1960), covering 1985 cases, the
5-year survival rate for operable cases presenting within 2 months (59 per cent)
was virtually identical to that for patients delaying for one vear or more (60 per
cent). When the patients with operable and inoperable tumours were considered
together the survival rate for cases with the shQrter history was 52 per cent com-
pared with 39 per cent for those with symptoms extending over one year or more.
A higher survival rate for women treated early was also seen in the series of over
10,000 unselected cases of breast cancer reported by the Registrar-General (1952).
Of 363 cases presenting within one month 44 per cent survived 5 years, compared
with 29 per cent of 487 cases who delayed for 5 to 6 months (Table XIX).
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TABLE XIX.-Survival According to Delay (10,025 Cases 1945-47)
Delay (months)
0- 1- 2- 3- 4- 5- 6- 9- 12- 18- 24+ Total
Cases 363 1075 1095 896 656 487 1287 483 1146 312 1601 10025
Crude survival % 44 42 39 35 35 29 29 31 27 31 27 33
Registrar-General (1952)
The necessity ofhaving histological sections for grading purposes in the present
series produced a bias in favour ofoperable cases, the tumours in 73 per cent being
in stages 1 and 2: 21 per cent ofthe cases were stage 3, and 6 per cent were stage 4.
Delay per se was found to have little influence on survival in these cases and it
was only by an indirect approach to the problem that prognosis was shown to
deteriorate with increasing duration of symptoms.
Clinical stagetakes into account the size oftheprimary tumour and thefeatures
of its local advancement in the breast, together with the condition of the axillary
nodes, all of which can be correlated individually with delay and with survival.
By considering histological grade we also have a direct measure of the intrinsic
malignancy ofthe tumour-aguideto thetempo ofthedisease. Itwasshownthat
as each grade of tumour advances in stage with increasing delay, so the survival
ratefalls.
The fact that certain potentially highly malignant grade III tumours appear
to be still confined to stage 1 when first seen, and carry 5-, 10- and 15-year crude
survival rates of approximately 70, 50 and 40 per cent, respectively, is perhaps
encouraging for those who strive to reduce delay in the hope of improving results.
What is likely to be gained by such efforts?
In more recent times duration ofsymptoms in breast cancer has become shorter
and more patients are being seen before the breast lesion has developed clinical
features offrank malignancy. Of 1000 cases ofmammary cancer at the Memorial
Hospital 21 per cent belonged to this category (Urban, 1960). The 5-year survival
rate for this group was 74 per cent compared with 52 per cent for those in whom a
clinical diagnosis of malignancy was made. Axillary node involvement was
present in only 32 per cent ofthe " early " cases compared with 60 per cent ofthe
remainder. The better prognosis for cases without obvious clinical manifestations
ofmalignancy was also seen in patientswith axillaryinvolvement by "high grade"
tumours (Urban, 1956).
Berger et at. (1963) found 110 cases of unsuspected breast carcinoma in 4688
patients studied by mammography. In 28 cases the tumour was impalpable.
Only 30 per cent of the 110 cases had axillary metastases. Gilbertson and
Wangensteen (1963) have recently reported preliminary results from the Cancer
Detection Service oftheUniversity ofMinnesota. Of 25 cases with asymptomatic
breast cancer treated by radical mastectomy 22 survived 5 years (88 per cent).
Only 6 cases had axillary metastases (25 per cent). There was only one death in 5
years among 19 patients in whom the axilla was free (95 per cent survival).
It would seem that the detection of very early clinical and even sub-clinical
breast cancer is possible before metastases have taken place, or at a time when
such metastases can be overcome by host resistance. The preliminary results from
cancer detection clinics are promising, but a prolonged follow-up of 15 years or
more will be required before one is able to say that these cases have probably been
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cured. It is too early to know whether the efforts required to seek out such cases
are practical or not. For example, Witten and Thurber (1964), using routine
mammography, were able to discover only 8 pre-clinical carcinomas among over
5000 women, 40 years of age or older, who had no significant breast complaints or
findings. The fact that it is possible in practice to detect a small number of
patients with early cancer of the breast and that in such cases treatment results
appear to be improved, is employed here solely to support the plea for trying to
reduce delay generally in this disease-the arguments, so far, having been based
entirely on retrospective studies.
Even in advanced cases delay has been shown toinfluenceprognosisappreciably.
Thus, in patients with involvement of apical axillary lymph nodes treated by
radical mastectomy at the Memorial Hospital, Robbins and Bross (1957) reported
that 36 per cent ofpatients who presented within 2 months were alive at 5 years,
compared with only 19 per cent of those who delayed for more than 6 months
(Table XX). A well-marked direct correlation between delay and survival,
however, especially in selected material, has not been the experience of most
investigators in this field.
TABLE XX.-" Level 3" Axillary Involvement and Prognosis
5-Year
Delay Cases survivals
(months) (%)
<2 . . 156 56 36
2-6 . . 100 28 28
>6 . 160 . 30 19
Total . . 416 . 114 27
From total of 1281 operable cases after Robbins and Bross (1957)
It is unlikely that prolongation of life by earlier diagnosis in breast cancer is
merely due to bringing forward the date oftreatment on what is, in point offact, a
fixed survival scale. Over 60 per cent of the total patients in the present series
attended hospital within 6 months, and over 80 per cent within 12 months, and
prognosis has been measured in terms of 5, 10 and 15 years or more.
Intrinsic tumour and host changes with time?
Certain further arguments may be mentioned here in favour of reducing delay
in breast cancer but, at the present time, these are largely speculative. With
increasing duration of symptoms changes in the tumour-host relationship might
occur which affect prognosis adversely. Thus, progression in the tumour to a less
responsive state is possible; that is, less responsive to treatment by irradiation or
by endocrine methods. For example, does prophylactic castration, which appears
to improve results in certain groups of patients, inhibit or even destroy occult
deposits and, with increasing delay, is the response ofsuch deposits reduced or lost?
During the period of waiting an alteration in hormonal balance may take place in
the patient which may affect the tumour adversely. Thus, endocrine changes
during pregnancy may be responsible for determining the character of a co-
incidentbreast cancerwhichisgenerally ofgrade IIItype, and carriesaparticularly
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poor prognosis (Bloom, 1962). With increasing delay does response to irradiatioin
alter, if not by virtue of a change in intrinsic properties, simply by an increase in
tumour volume with the development of poorly oxygenated areas?
Can tumour grade alter with time, and during the period ofdelay progress to a
more malignant type? Occasionally de-differentiation seems to take place in
established tumours such as in certain cerebral gliomas. A recurrent astrocytoma,
for example, may be of higher grade than the original lesion excised several years
previously. On the other hand, grade of malignancy in breast cancer appears to
be remarkably stable, the histological appearance of metastases presenting 10 or
more years after radical mastectomy closely resembling that ofthe primary tumour
(Bloom and Richardson, 1957).
A well-marked lymphocytic and plasma cell reaction in certain well-circum-
scribed breast tumours of apparently high grade malignancy (" medullary car-
cinoma ") is associated with a good prognosis (Moore and Foote, 1949; Richard-
son, 1956), and may reflect a high degree ofhost resistance to the tumour. Further
support for this concept has been presented by Hultborn and T6rnberg (1960) and
by Berg (1959, 1962) who also find an improved outlook for patients with breast
cancer associated with round cell infiltration. Another factor which may be a
measure of host reaction to breast cancer and ofvalue in prognosis is the degree of
sinus hyperplasia in the axillary lymph nodes (Black et al., 1955, 1956 ; Black and
Speer, 1958; Wartmann, 1959; DiRe and Lane, 1963), although Berg (1956)
and also Moore et al. (1960) have been unable to confirm this. It is interesting to
consider whether these reactions, claimed to represent host resistance, may be
modified unfavourably during a period of delay by, for example, endocrine
changes, local infection or intercurrent disease.
In his monograph on the significance of delay in cancer in general, Sutherland
(1960) deals at some length with host resistance factors and this subject has also
been reviewed recently by Southam (1961). Until the above questions can be
answered it would seem reasonable to strive for prompt treatment in breast cancer,
not only to deal with the tumour at an early stage, but also to reduce the chance of
deleterious changes taking place with time in the tumour-host relationship.
McKinnon's (1955) view that many stage 1 breast tumours diagnosed as
carcinoma, in patients who subsequently do well following treatment, are not
really malignant is quite untenable. All cases in the present series, including the
grade I cases, were examples of histologically confirmed invasive carcinoma. On
the other hand, it may be argued that good results from treatment ofbreast cancer
are mainly found in patients with what appear to be naturally favourable tumours.
Although this is undoubtedly correct it should not be employed to decry the value
of treatment in general since breast cancer, even of low grade malignancy, does
advance, metastasize and eventually kill the host if untreated. Furthermore,
even in those patients where there is the suggestion of a high natural resistance,
such as cases of " medullary carcinoma ", death will occur from widespread disease
if therapy is inadequate (Richardson, 1956).
Fifteen years ago the present author expressed the view that outcome in
mammary cancer was largely determined by the biological character of the
tumour, reflected in the histological grade, rather than by prompt treatment
(Bloom, 1950b). Macdonald (1942) has voiced a similar opinion over a longer
period. Although in the main this view must still be upheld it nevertheless appears
that delay may lose years oflife and comfort for many patients, especially for those
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with tumours of intermediate and of low grade malignancy. It is perhaps just
those women who delay for long periods with tumours of relatively low grade
malignancy, or with a high natural resistance, who may have a better prognosis or
chance of cure if they were treated at an earlier date. Radical treatment in a
particular case might have been feasible some months previously whereas now only
palliation is possible.
With the passing years an improvement in the results of breast cancer treat-
ment has been reported by a number of observers (Adair, 1949; Taylor, 1949,
Harrington, 1952; Haagensen, 1956). The average delay in seeking medical
advice after onset of symptoms also appears to be shorter (Harrington, 1946;
Leach and Robbins, 1947; Nohrman, 1949; Moore and Shaw, 1957). At the
same time the proportion of patients presenting with smaller tumours, negative
axillary nodes, limited node involvement, or in stage 1 of the disease, is greater
(Moore and Shaw, 1957; Berkson et al., 1957; Robbins et al., 1959; McSwain and
Fleming, 1963). These changes are considered to be responsible for the improve-
ment in survival rate seen in recent years in some centres (Moore and Shaw,
1957; Berkson et al., 1957). At the Mayo Clinic the increase in survivals is
confined to patients with positive axillary nodes (Berkson et al., 1957). This is
probably also due to the treatment of earlier and less advanced cases, prognosis
being not only related to the presence or absence of axillary metastases, but also
to the number and level of nodes involved.
Unlike the vague symptoms so often associated with the clinical onset of
malignant disease involving internal organs, cancer of the breast provides the
patient with objective, tangible evidence of its existence-a lump, which is the
first symptom in over 80 per cent of cases. In spite of the present-day education
and publicity on medical matters received by the general public, there is still in
many places a distressingly high proportion of women who delay seeking advice
for a breast tumour. Of 943 patients seen between the years 1955 and 1959 in
London at the Royal Marsden Hospital no less than 50 per cent presented with a
primary tumour greater than 5 cm., or with skin ulceration (Harmer, 1962). It is
difficult to believe that in these circumstances the best possible prognosis is being
secured for patients with breast cancer.
In previous communications (Bloom et al., 1962; Bloom, 1964) the benefit to
be derived from treatment per 8e in breast cancer was emphasised by considering
the natural history of the untreated disease. In the present paper the effects of
delay on the tumour anid perhaps the host have been reviewed and now a plea is
made for early diagnosis and prompt treatment. Before closing, however, it is
important to stress that, since half the patients who appear to come early for
treatment already have axillary node involvement, the overall improvement in
survival resulting from efforts to reduce delay alone islikely to belimited. Before
we can materially alter the outlook for many cases we may have to wait for new
methods of treatment. On the other hand, Robbins and Bross (1957) were able
to demonstrate a profound effect ofdelay even in advanced cases who were treated
by standard radical surgery (Table XX). We surely cannot avoid striving to
reduce the delay period in all patients for the sake ofthe limited number whoselife
may thereby be saved, and for a greater number of others who are likely to gain
time and comfort: because of the possible benefit for the individual which can be
so easily overlooked in mass statistics, early treatment must be the undoubted
principle for all cases.
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SUMMARY
Most authors are unable to demonstrate an appreciable deterioration in
prognosis in breast cancer with increasing duration of symptoms. In the present
series of over 1200 cases treated chiefly by radical mastectomy with or without
ancillary irradiation, delay in treatment did not appear to influence prognosis
adversely, as judged by the 5- to 20-year survival rates. The outlook for patients
presenting at hospital within 3 months was identical to that for cases coming after
a delay of one year or more. It was only when attention was given to intrinsic
tumour malignancy and to the influence oflost time on the tumour itself, that the
harmful effect of delay in treatment could be demonstrated.
Between the onset ofsymptoms and the institution oftreatment breast cancer,
as judged by individual tumour factors, clearly tends todevelop moreunfavourable
characteristics. With increasing delay smaller tumours are found less frequently
and larger tumours more often. As time passes not only do more cases develop
axillary metastases, but the extent of this involvement increases, as judged by
the number and level of nodes invaded. The larger the primary tumour the
higher theincidence ofaxillarydeposits. Thegreater the degree ofaxillaryinvolve-
ment the greater the risk of spread to other regional nodes. As delay increases
fewer patients with low stage tumours and more with high stage lesions are seen:
the proportion of inoperable cases becomes greater. With advancing stage the
median and upper quartile periods of delay become longer.
Since all the above tumour factors can be shown to advance with increasing
duration of symptoms, and since increasing changes in the tumour are associated
with a falling survival rate, delay itself must affect prognosis adversely.
A reason for the failure to demonstrate a direct correlation between delay and
survival became evident after taking into account the intrinsic malignancy of the
tumour, based on histological grade. The more rapidly growing and more lethal
grade III tumours tend especially to be found in patientswho seek early treatment,
presumably because this type of tumour produces more alarming symptoms. On
the other hand, the essentially less malignant grade I lesions are found more often
in patients with a long history. The distribution of tumour grades tends to
counterbalance the influence of delay on survival rate.
By employing histological grade in thestudy ofbreastcancerthebroadspectrum
ofmalignancy which exists in any group ofpatients with this disease is more fully
appreciated. Those patients seeking advice within, for example, 3 months, are
composed ofwomenwith small and large tumours ofdifferent grades ofmalignancy,
and with a 5-year survival rate ranging from 87 per cent to 30 per cent.
The effect of delay on various individual tumour factors was re-examined in
the light of tumour grade. Since clinical stage takes into account many of the
local features of the breast lesion, together with the state of the axillary nodes,
the simplest and most comprehensive account of mammary cancer appears to be
given by a combination of histological grade and clinical stage. This provides a
guide to the intrinsic properties of the tumour, including the tempo ofthe disease,
and is a measure of the obvious extent of the lesion when first seen.
As each grade of tumour advances in stage so the median and upper quartile
periods of delay increase. The higher the grade, the quicker this advance takes
place.
With increasing delay for each grade of tumour, the incidence of stage 1 cases
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decreases, whilst that ofstage 3 cases becomes greater. The relative proportion of
these stages at anygiven time depends upon tumourgrade, thehigher thegradethe
sooner the more advanced cases predominate.
The survival rate falls markedly with increasing stage, and the extent of this
deterioration depends upon tumour grade. A combined classification using stage
and grade provides a more accurate guide to prognosis than either factor alone,
and within the framework ofthis classification the influence ofdelay can be seen.
By means of the combined classification it was possible to show that tumours
of all stages and grades are represented among cases seeking early advice (within
3 months). Such cases had a 5-year survival rate ranging from as high as 88 per
cent for women with stage 1, grade I carcinomas to only 14 per cent for those with
stage 3, grade III lesions. Within the limits of a single stage, stage 2, the survival
rate for patients attending hospital within 3 months with grade I tumours was
84 per cent, compared with only 24 per cent for those with grade III lesions. An
equally striking variety of cases was found even among women harbouring breast
tumours for more than a year. It is, therefore, impossible to assess the influence
of delay on survival in breast cancer without a classification which takes into
account the wide variation in type of case met with at all times in this disease.
It was speculated that certain intrinsic factors such as grade, hormonal respon-
siveness and radiosensitivity of the tumour, and possibly resistance of the host,
might be modified unfavourably during the interval between a patient finding a
breast lump and seeking advice.
Since almost halfthe patients with breast cancer who appear to seek treatment
early already have axillary metastases, the overall improvement in survival rate
resulting from efforts to reduce delay is likely to be limited. On the other hand,
since halfthe patients with this disease attending a cancer hospital in a large city
seek advice only when their tumours are greater than 5 cm., or ulcerated, itis
difficult to believe that present day methods oftreatment are achieving the best
possible results. Patients who come late for treatment often have tumours oflow
grade malignancy, and it may be just these cases that will benefit most from efforts
to reduce delay.
In a previous communication the author and his colleagues (Bloom, Richardson
and Harries, 1962) emphasised the importance oftreatment per se in breast cancer
by considering the natural history ofthe untreated disease. In the present paper
the effectsofdelay in treatment on the tumour and possibly also on host resistance
have been reviewed, and a plea is made for efforts to reduce loss oftime. Because
of the chance of saving or prolonging useful life for the individual, a factor often
overlooked in mass statistics, early treatment must be the undoubted principle for
all cases of breast cancer.
I am grateful to the medical staff of the Middlesex Hospital for the cases
employed in this study and to Mr. T. E. Cowan of the Records Department for
follow-up data. I remain indebted to Professor R. W. Scarff ofthe Bland-Sutton
Institute for introducing me to the subject of tumour grading. The histological
sections oftwo-thirds ofthe cases in this series were formerly studied in collabora-
tion with Mr. W. W. Richardson and were part ofthe material for our joint paper
on grading of breast cancer.
My thanks are due to Mr. P. Payne, Director ofthe S.E. Metropolitan Cancer
Registry, for his advice and help in assembling the statistical data.
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I should also like to thank the Departments ofMedical Art and Photography of
the Royal Marsden Hospital for the figures. Fig 7 and 8 have been reproduced
by kind permission of the New York Academy of Sciences.
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